Zentalis Pharmaceuticals Q3 net loss narrows

Reuters11-11

Zentalis Pharmaceuticals Q3 net loss narrows

Overview

Zentalis Q3 operating expenses decreased to $33.7 mln from $51.4 mln last year
Net loss for Q3 2025 was $26.7 mln, an improvement from $40.2 mln last year
Company has $280.7 mln in cash, supporting operations into late 2027

Outlook

Company's cash supports operations into late 2027

Result Drivers

COST REDUCTION - Decrease in R&D expenses contributed to lower operating expenses for the quarter
STRONG CASH POSITION - Company has $280.7 mln in cash, supporting operations into late 2027

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.37
Q3 Net Income		-$26.69 mln
Q3 Operating Expenses		$33.73 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 76.7% above its November 7 closing price of $1.28

Press Release: ID:nGNX24RF7F

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582800072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582800072","market":"us","top_or_hot":-1,"title":"Zentalis Pharmaceuticals Q3 net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Zentalis Pharmaceuticals Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Zentalis Q3 operating expenses decreased to $33.7 mln from $51.4 mln last year</p></li><li><p>Net loss for Q3 2025 was $26.7 mln, an improvement from $40.2 mln last year</p></li><li><p>Company has $280.7 mln in cash, supporting operations into late 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company's cash supports operations into late 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST REDUCTION - Decrease in R&amp;D expenses contributed to lower operating expenses for the quarter</p></li><li><p>STRONG CASH POSITION - Company has $280.7 mln in cash, supporting operations into late 2027</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.37</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$26.69 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$33.73 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 5 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 76.7% above its November 7 closing price of $1.28</p></li></ul><p>Press Release: <span>ID:nGNX24RF7F</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zentalis Pharmaceuticals Q3 net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZentalis Pharmaceuticals Q3 net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Zentalis Pharmaceuticals Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Zentalis Q3 operating expenses decreased to $33.7 mln from $51.4 mln last year</p></li><li><p>Net loss for Q3 2025 was $26.7 mln, an improvement from $40.2 mln last year</p></li><li><p>Company has $280.7 mln in cash, supporting operations into late 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company's cash supports operations into late 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST REDUCTION - Decrease in R&amp;D expenses contributed to lower operating expenses for the quarter</p></li><li><p>STRONG CASH POSITION - Company has $280.7 mln in cash, supporting operations into late 2027</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.37</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$26.69 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$33.73 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 5 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 76.7% above its November 7 closing price of $1.28</p></li></ul><p>Press Release: <span>ID:nGNX24RF7F</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZNTL","symbol_name":"Zentalis Pharmaceuticals, LLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM12Y:1","article_id":"2582800072","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582800072","pubTimestamp":1762809468,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zentalis Pharmaceuticals Q3 net loss narrowsOverviewZentalis Q3 operating expenses decreased to $33.7 mln from $51.4 mln last yearNet loss for Q3 2025 was $26.7 mln, an improvement from $40.2 mln last","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZNTL":"Zentalis Pharmaceuticals, LLC","BK4139":"生物科技"},"translate_title":"Zentalis制药第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZNTL":0.9},"content_text":"Zentalis Pharmaceuticals Q3 net loss narrowsOverviewZentalis Q3 operating expenses decreased to $33.7 mln from $51.4 mln last yearNet loss for Q3 2025 was $26.7 mln, an improvement from $40.2 mln last yearCompany has $280.7 mln in cash, supporting operations into late 2027OutlookCompany's cash supports operations into late 2027Result DriversCOST REDUCTION - Decrease in R&D expenses contributed to lower operating expenses for the quarterSTRONG CASH POSITION - Company has $280.7 mln in cash, supporting operations into late 2027Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.37Q3 Net Income-$26.69 mlnQ3 Operating Expenses$33.73 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 5 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 76.7% above its November 7 closing price of $1.28Press Release: ID:nGNX24RF7FFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582800072","isCrawlerRequest":true}